首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1378694

急性缺血性脑中风(AIS) 市场：依药物、配销通路、地区分类

Acute Ischemic Stroke Market, By Therapeutics, By Distribution Channel, By Geography

出版日期: 2023年10月18日 | 出版商:

Coherent Market Insights | 英文 149 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计到 2023 年，全球急性缺血性脑中风(AIS) 市场规模将达到 92.1 亿美元，预计在预测期内（2023-2030 年）年复合成长率为 4.0%。

报告范围		报告详情
基准年	2022年	2023年市场规模	92.1亿美元
实绩资料	2018-2021	预测期	2023-2030
预测期年复合成长率	4.00%	2030年市场规模预测	121.2亿美元

图 1. 2023 年按治疗药物分類的急性缺血性脑中风(AIS) 的全球市场占有率(%)

当大脑动脉中的血流被血栓（一种增厚的血块）阻塞时，就会发生急性缺血性脑中风（AIS）。根据血栓在体内形成的位置，血栓分为血栓性或栓塞。最常见的中风类型是血栓性中风，当脑动脉形成血块时就会发生这种情况。当栓塞或小块斑块（脂肪沉积物）从心臟或身体其他部位脱落，进入血液并滞留在大脑的小血管中时，就会发生栓塞中风。大血管阻塞（LVO）约占急性缺血性脑中风的一半。 LVO 是最严重、最使人衰弱的中风类型，因为血块阻塞了大动脉，阻碍了血液流向大脑的重要部位。

市场动态

无机成长策略的增加，例如主要市场参与企业结盟以扩大产品系列，预计将在预测期内推动全球急性缺血性脑中风（AIS）市场的成长。例如，2021年12月，生物科技公司先声药业集团有限公司与专注于开发神经系统疾病创新药物的临床阶段生物科技公司Avilex Pharma（Avilex）宣布，双方将宣布建立战略区域许可合作伙伴关係，共同开发和商业化靶向突触后密度蛋白 95 (PSD-95) 的药物可治疗急性缺血性脑中风(AIS) 和其他神经系统疾病。该协议授予先声药业集团有限公司独家区域许可，以开发和商业化 Avilex 的 2-ready 二聚体 PSD-95 抑制剂 AVLX-144，用于治疗 AIS 和其他神经系统疾病。 AVLX-144 是一种胜肽样候选药物，用于治疗 AIS，其靶向细胞内支架蛋白 PSD-95。 AVLX-144 是一种广泛最佳化的二聚体 PSD-95 抑制剂，也是治疗 AIS 和蛛网膜下腔出血 (SAH) 等急性疾病的临床主要候选药物。

本研究的主要特点

本报告对全球急性缺血性脑中风（AIS）市场进行了详细分析，并列出了以2022年为基准年的预测期（2023-2030年）的市场规模和年复合成长率。
它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
本报告根据公司亮点、产品系列、主要亮点、绩效和策略等参数，介绍了全球急性缺血性脑中风(AIS) 市场的主要企业。
该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的资讯。
全球急性缺血性脑中风(AIS) 市场迎合该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于分析全球急性缺血性脑中风（AIS）市场的各种策略矩阵，将有助于相关人员做出决策。

公司简介
- F. Hoffmann-La Roche Ltd
- Boehringer Ingelheim International GmbH
- Bayer AG
- Pfizer Inc.
- Biogen
- DAIICHI SANKYO COMPANY, LIMITED
- Bristol-Myers Squibb Company
- Johnson &Johnson Services, Inc.
- AstraZeneca
- SanBio Co,Ltd.
- Athersys, Inc.
- Abbott
- Sanofi
- ZZ Biotech
- Teva Pharmaceutical Industries Ltd
- Merck &Co., Inc.
- NoNO Inc.
- AliveCor, Inc.
- Amgen Inc.
- Genentech USA, Inc.
- DiaMedica Therapeutics, Inc.

第9章章节

参考
调查方法

简介目录

Product Code: CMI4483

Global acute ischemic stroke (AIS) market is estimated to be valued at US$ 9.21 Bn in 2023, and is expected to exhibit a CAGR of 4.0% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 9.21 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	4.00%	2030 Value Projection:	US$ 12.12 Bn

Figure 1. Global Acute Ischemic Stroke (AIS) Market Share (%), By Therapeutics, 2023

Acute ischemic stroke (AIS) occurs when blood flow through a brain artery is obstructed by a clot, which is a thickened mass of blood. Clots are classified as either thrombotic or embolic depending on where these form in the body. The most common type of stroke is a thrombotic stroke thatoccurs when a clot forms within a brain artery. An embolic stroke occurs when a clot or small piece of plaque (fatty deposit) breaks off from another part of the body such as the heart, and travels through the bloodstream before becoming lodged in a narrower vessel in the brain. Large vessel occlusion (LVO) is responsible for nearly half of all acute ischemic strokes. LVO is the most serious and debilitating type of stroke because the clot blocks large arteries, and prevents blood flow to essential parts of the brain.

Market Dynamics

Increasing inorganic growth strategies such as partnership by key market players, in order to expand their product portfolio is expected to drive the global acute ischemic stroke (AIS) market growth over the forecast period. For instance, in December 2021, Simcere Pharmaceutical Group Ltd, a biotechnology company, and Avilex Pharma (Avilex), a clinical-stage biotechnology company that focuses on developing innovative medicines for neurological disorders, announced a strategic regional licensing partnership to develop and commercialize medicines that target the postsynaptic density protein 95 (PSD-95) to treat acute ischemic stroke (AIS) and other neurological conditions in greater China. The agreement granted Simcere Pharmaceutical Group Ltd an exclusive regional license to develop and commercialize AVLX-144, Avilex's 2-ready dimeric PSD-95 inhibitor, for the treatment of AIS and other neurological conditions. AVLX-144 is a dimeric peptide-like drug candidate for the treatment of AIS that targets the intracellular scaffolding protein- PSD-95. AVLX-144 is an extensively optimized dimeric PSD-95 inhibitor and a clinical lead candidate for the treatment of acute conditions such as AIS and subarachnoid hemorrhage (SAH).

Key features of the study:

This report provides an in-depth analysis of the global acute ischemic stroke (AIS) market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global acute ischemic stroke (AIS) market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include F.Hoffmann-La Roche Ltd, Boehringer Ingelheim International GmbH, Bayer AG, Pfizer Inc., Biogen, DAIICHI SANKYO COMPANY, LIMITED, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., AstraZeneca, SanBio Co,Ltd., Athersys, Inc., Abbott, Sanofi, ZZ Biotech, Teva Pharmaceutical Industries Ltd, Merck & Co., Inc., NoNO Inc., AliveCor, Inc., Amgen Inc., Genentech USA, Inc., and DiaMedica Therapeutics, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global acute ischemic stroke (AIS) market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute ischemic stroke (AIS) market

Acute Ischemic Stroke (AIS) Market Detailed Segmentation:

By Therapeutics:
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Company Profiles
- F. Hoffmann-La Roche Ltd
- Boehringer Ingelheim International GmbH
- Bayer AG
- Pfizer Inc.
- Biogen
- DAIICHI SANKYO COMPANY, LIMITED
- Bristol-Myers Squibb Company
- Johnson & Johnson Services, Inc.
- AstraZeneca
- SanBio Co,Ltd.
- Athersys, Inc.
- Abbott
- Sanofi
- ZZ Biotech
- Teva Pharmaceutical Industries Ltd
- Merck & Co., Inc.
- NoNO Inc.
- AliveCor, Inc.
- Amgen Inc.
- Genentech USA, Inc.
- DiaMedica Therapeutics, Inc.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Therapeutics
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics

Drivers
Restraints
Opportunities
- Impact Analysis
- Recent Trends
- Product Launches and Approvals
- Mergers, Acquisitions, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- PORTER's Analysis

4. Global Acute Ischemic Stroke (AIS) Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Acute Ischemic Stroke (AIS) Market, By Therapeutics, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Tissue Plasminogen Activator
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Anticoagulant
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Antiplatelet
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Antihypertensive
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

6. Global Acute Ischemic Stroke (AIS) Market, By Distribution Channel, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospitals Pharmacies
- Introduction
- Market Size and Forecast and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

7. Global Acute Ischemic Stroke (AIS) Market, By Region, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018 -2030, (US$ Bn)
North Africa
Central Africa
South Africa

8. Competitive Landscape

Company Profiles
- F. Hoffmann-La Roche Ltd
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Boehringer Ingelheim International GmbH
- Bayer AG
- Pfizer Inc.
- Biogen
- DAIICHI SANKYO COMPANY, LIMITED
- Bristol-Myers Squibb Company
- Johnson & Johnson Services, Inc.
- AstraZeneca
- SanBio Co,Ltd.
- Athersys, Inc.
- Abbott
- Sanofi
- ZZ Biotech
- Teva Pharmaceutical Industries Ltd
- Merck & Co., Inc.
- NoNO Inc.
- AliveCor, Inc.
- Amgen Inc.
- Genentech USA, Inc.
- DiaMedica Therapeutics, Inc.

9. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

急性缺血性脑中风(AIS) 市场：依药物、配销通路、地区分类

Acute Ischemic Stroke Market, By Therapeutics, By Distribution Channel, By Geography

市场动态

本研究的主要特点

目录

第1章调查目的和假设

第2章市场展望

第3章市场动态、法规及趋势分析

第4章全球急性缺血性脑中风(AIS) 市场 - COVID-19感染疾病的影响分析

第5章2018-2030 年全球急性缺血性脑中风(AIS) 市场（依治疗药物）

第6章全球急性缺血性脑中风(AIS) 市场（按配销通路），2018-2030 年

第7章全球急性缺血性脑中风(AIS) 市场（按地区）2018-2030 年

第8章竞争形势